Ipilimumab

Generic Name
Ipilimumab
Brand Names
Yervoy
Drug Type
Biotech
Chemical Formula
-
CAS Number
477202-00-9
Unique Ingredient Identifier
6T8C155666
Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication

Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions
Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
First Line Chemotherapy
Clinical Trials
Related News

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Phase 1
Recruiting
Conditions
Melanoma
Interventions
Drug: Ipilimumab
Drug: Nivolumab
First Posted Date
2024-02-02
Last Posted Date
2024-11-14
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
96
Registration Number
NCT06240143
Locations
🇳🇱

Amsterdam University Medical Center, Amsterdam, Netherlands

🇳🇱

Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

🇳🇱

University Medical Center Groningen, Groningen, Netherlands

and more 3 locations

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

First Posted Date
2023-12-11
Last Posted Date
2023-12-27
Lead Sponsor
Melanoma and Skin Cancer Trials Limited
Target Recruit Count
46
Registration Number
NCT06163820

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

First Posted Date
2023-10-24
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT06097728
Locations
🇬🇧

Research Site, Taunton, United Kingdom

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

First Posted Date
2023-09-22
Last Posted Date
2024-12-11
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
30
Registration Number
NCT06049576
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

First Posted Date
2023-09-21
Last Posted Date
2024-10-16
Lead Sponsor
Neonc Technologies, Inc.
Target Recruit Count
134
Registration Number
NCT06047379
Locations
🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

First Posted Date
2023-09-11
Last Posted Date
2024-03-07
Lead Sponsor
Isala
Target Recruit Count
679
Registration Number
NCT06031233
Locations
🇳🇱

Isala Hospital, Zwolle, Netherlands

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

First Posted Date
2023-08-14
Last Posted Date
2024-12-09
Lead Sponsor
IDEAYA Biosciences
Target Recruit Count
420
Registration Number
NCT05987332
Locations
🇺🇸

Honor Health, Scottsdale, Arizona, United States

🇺🇸

Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

and more 63 locations

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

First Posted Date
2023-07-03
Last Posted Date
2024-10-23
Lead Sponsor
Michael B. Atkins, MD
Target Recruit Count
120
Registration Number
NCT05928806
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Yale University, Yale Cancer Center, New Haven, Connecticut, United States

and more 9 locations

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

First Posted Date
2023-07-03
Last Posted Date
2024-12-03
Lead Sponsor
Pfizer
Target Recruit Count
150
Registration Number
NCT05926960
Locations
🇮🇹

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

🇮🇹

Istituto Europeo di Oncologia IRCCS, Milano, Italy

🇸🇰

Nemocnica Poprad, a.s., Poprad, Slovakia

and more 60 locations

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

First Posted Date
2023-06-27
Last Posted Date
2024-12-17
Lead Sponsor
Servier Bio-Innovation LLC
Target Recruit Count
7
Registration Number
NCT05921760
Locations
🇺🇸

UCSF - Medical Center at Mission Bay, San Francisco, California, United States

🇺🇸

Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy